Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: A meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 366-375

  As Sultany, Mohammed ^a   Pagkalos, Joseph ^b   Yeganeh, Sara ^c   Craigs, Cheryl L ^d   Korres, Nectarios ^e   West, Robert M ^d   Tsiridis, Eleftherios ^e,f  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c YEOVIL DISTRICT HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Direct FXa inhibitors; Low molecular weight heparin; Meta analysis; Oral anticoagulants; Total hip arthroplasty; Total knee arthroplasty; Venous thromboembolism

Indexed keywords

APIXABAN; ENOXAPARIN; RIVAROXABAN;

BLEEDING; DRUG EFFECT; DRUG SAFETY; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LUNG ANGIOGRAPHY; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOGRAPHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR XA; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84878659179     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030011     Document Type: Review

References (88)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl 1): 132S-175S.
2. th Edition). Chest 2008; 133: 381S-453S.
3. National Institute of Clinical Excellence (NICE). Venous throm-boembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. Clinical guideline 46. April 2007.
4. Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. A national clinical guideline. Edinburgh: SIGN Publication, 2002.
5. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the hip and knee registry. Chest 2003; 124: 349S-56S.
6. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799-807.
7. Agnelli G. Current issues in anticoagulation. Pathophysiol Haemost Thromb 2005; 34 (Suppl 1): 2-9.
8. Eriksson BI, Quinlan D. Oral anticoagulants in development: Focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66 (11): 1411-1429.
9. Hirch J, O'Donnell M, Erikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560.
10. McBride BF. A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. J Clin Pharmacol 2005; 45: 1004-1017.
11. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinet-ics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced throm-bocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
13. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-112.
14. Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636.
15. Bara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 1988; 543: 65-72.
16. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerised heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101.
17. th edition). Chest 2008; 133 (6 Suppl.): 160S-198S.
18. Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Management 2008; 4: 1373-1386.
19. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; 5 (Suppl 1): 60-64.
20. Weitz JI. Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 2007; 5 (Suppl 1): 65-7.
21. st August 2011).
22. st August 2011).
23. st August 2011).
24. st August 2011).
25. st August 2011).
26. st August 2011).
27. st August 2011).
28. st August 2011).
29. st August 2011).
30. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reportin Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ 2009; 339: b2535.
31. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
32. Committee for Proprietary Medicinal Products. Recommendations on the need for revision of the guidelines on clinical investigation of medicinal products for prophylaxis of high intra- and postoperative venous thromboembolic risk. London: The European Agency for the Evaluation of Medicinal Products. 2005 Nov 17. Guideline no. CPMP/EWP/707/98.
33. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
34. Lassen MR, Bauer KA, Eriksson BI, Turoie AG. Effect on efficacy and safety of the timing of the first fondaparinux administration for the thromboprophylaxis in orthopaedic surgery. J Bone Joint Surg Br 2004; 86-B (Suppl 3): 232.
35. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thrombo-embolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
36. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
37. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Superiority of fondaparinux over enoxaparin in preventing venous thromboem-bolism in major orthopaedic surgery using different efficacy end-points. Chest 2004; 126: 501-508.
38. Singelyn FJ, Verheyen CC, Piovella F, Van Aken HK, Rosencher N. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopaedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 2007; 105: 1540-1547.
39. Ottinger JG. Retrospective evaluation of delayed administration of fondaparinux in providing comparable safety and efficacy outcomes in patients undergoing elective-arthroplasty procedures. Hosp Pharm 2006; 41: 348-353.
40. No authors listed. A study of DU-176b in preventing blood clots after hip replacement surgery. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00398216 completed June 2007.
41. No authors listed. Study of the efficacy and safety of DU-176b in preventing blood clots in patients undergoing total hip replacement. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00107900 completed December 2005.
42. No authors listed. A phase 2b study of DU-176b, prevention of venous thromboembolism in patients after total hip arthroplasty. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT01203098 completed June 2009.
43. No authors listed. A study of DU-176b, prevention of venous thromboembolism in patients after total hip arthroplasty. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT01181167 completed March 2010.
44. No authors listed. A phase 3 study of DU-176b, prevention of venous thromboembolism in patients after total knee arthroplasty. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT01181102 completed February 2010.
45. No authors listed. Prevention of venous thromboembolism in patients undergoing elective total hip replacement surgery. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00913120 completed March 2010.
46. No authors listed. Prevention of venous thromboembolism in patients undergoing elective total knee replacement surgery. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00917254 completed January 2010.
47. No authors listed. A study evaluating efficacy and safety of YM150 compared to enoxaparin in subjects undergoing hip replacement surgery (ONYX-3). National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00902928 completed June 2010.
48. No authors listed. A study to evaluate the safety and efficacy of YM150 in patients with knee replacement (PEARL). National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00595426 completed May 2009.
49. No authors listed. Factor Xa inhibitor for preventing of venous thromboembolism in patients undergoing elective total knee re-placement (PEARL-1). National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00408239 completed March 2009.
50. No authors listed. Efficacy and safety of TAK-442 in subjects undergoing total knee replacement. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00641732 completed October 2008.
51. No authors listed. Efficacy and safety of TAK-442 in subjects undergoing total knee replacement. National Institutes of Health Clinical Trials Database (USA). Available from: http://www.clinicaltrials.gov.NCT00641732 completed October 2008.
52. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokine-tics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
53. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
54. Agnelli G, Hass S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007; 5: 746-753.
55. Eriksson BI, Turpie AG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5: 1660-1665.
56. Eriksson BI, Turpie AG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010; 8: 714-721.
57. Turpie AG, Bauer KA, Davidson BL, et al. A randomised evaluation of betrixaban, an oral factor Xa inhibitor, for the prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101: 68-76.
58. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboem-bolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-2486.
59. Lassan MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomised, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003; 102: 15a: Abstract.
60. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivarox-aban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
61. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
62. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxa-parin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
63. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophy-laxis after total hip replacement. Circulation 2006; 114: 2374-2381.
64. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboem-bolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
65. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-693.
66. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
67. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxa-parin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
68. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
69. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD-4): a randomised trial. Lancet 2009; 373: 1673-1680.
70. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
71. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynam-ics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
72. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for throm-boprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thromb Haemost 2007; 97: 931-937.
73. Eriksson BI, Kakkar AK, Turpie AGG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. JBJS [Br] 2009; 91: 636-644.
74. Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxa-parin for thromboprophylaxis after total hip and knee arthroplasty: a meta-analysis of randomised controlled trials. Eur J Clin Pharmacol 2010; 66: 1099-2108.
75. Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip and knee arthro-plasty: Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
76. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
77. Van der Heijden JF, Prins MH, Büller HR. For the initial treatment of venous thromboembolis: are all low-molecular-weight heparin compounds the same? Thromb Res 2000; 100: 121-130.
78. Fareed J, Hoppensteadt D, Schultz C, et al. Biochemical and phar-macologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 2004; 10: 983-999.
79. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins -dalteparin, enoxaparin and nadroparin - administered subcutane-ously in healthy volunteers (doses for prevention of thromboem-bolism). Thromb Haemost 1995; 73: 630-640.
80. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: A systematic review. Arch Intern Med 2001; 161: 1952-1960.
81. Strebel N, Prins M, Agnelli G, Büller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-1456.
82. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxa-parin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxa-parin Clinical Trial Group. J Bone Joint Surg Am 1994; 76: 3-14.
83. Colwell CW Jr, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop Relat Res 1995; 319: 215-222.
84. Minnema B, Vearncombe M, Augustin A, Gollish J, Simor AE. Risk factors for surgical site infection following primary total knee arthroplasty. Infect Control Hosp Epidemiol 2004; 25: 477-480.
85. Krizek T, Davis J. The role of the red cell in subcutaneous infection. J Trauma-Injury Infect Crit Care 1965; 5: 85-95.
86. van Veen JJ, Maclean RM, Hampton KK, et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Co-agul Fibrinolysis 2011; 22:565-570.
87. Tinel H, Huetter J, Perzborn E. Recombinant factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban: a novel, oral factor Xa inhibitor in rats. J Thromb Haemost 2007; 5 (Suppl 2): Abstract.
88. Perzborn E, Harwardt M. Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on throm-bin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost 2007; 5 (Suppl 2): Abstract.